Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC (NYSE:LLY)

PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).

Under the terms of the agreement, Sanofi acquires the exclusive rights to apply for approval of Cialis OTC in the United States, Europe, Canada and Australia. Sanofi also holds exclusive rights to market Cialis OTC followingSanofi's receipt of all necessary regulatory approvals. If approved, Sanofi anticipates providing Cialis OTC after expiration of certain patents. Terms of the licensing agreement were not disclosed.

Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC (NYSE:LLY)